VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer

Janelle C. Arthur¹, Raad Z. Gharaibeh⁴, Joshua M. Uronis¹, Ernesto Perez-Chanona², Wei Sha⁴, Sarah Tomkovich³, Marcus Mühlbauer¹, Anthony A. Fodor⁵ & Christian Jobin¹,²,³,⁶,⁷

¹Department of Medicine, ²Pharmacology, ³Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA, ⁴Bioinformatics Services Division, Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Kannapolis, NC 28081, USA, ⁵Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, NC 28223, USA, ⁶Department of Medicine, University of Florida at Gainesville, Gainesville, FL32611, USA, ⁷Department of Infectious Diseases and Pathology, University of Florida at Gainesville, Gainesville, FL32611, USA.

Although probiotics have shown success in preventing the development of experimental colitis-associated colorectal cancer (CRC), beneficial effects of interventional treatment are relatively unknown. Here we show that interventional treatment with VSL#3 probiotic alters the luminal and mucosally-adherent microbiota, but does not protect against inflammation or tumorigenesis in the azoxymethane (AOM)/Il10²/² mouse model of colitis-associated CRC. VSL#3 (10⁹ CFU/animal/day) significantly enhanced tumor penetrance, multiplicity, histologic dysplasia scores, and adenocarcinoma invasion relative to VSL#3-untreated mice. Illumina 16S sequencing demonstrated that VSL#3 significantly decreased (16-fold) the abundance of a bacterial taxon assigned to genus Clostridium in the mucosally-adherent microbiota. Mediation analysis by linear models suggested that this taxon was a contributing factor to increased tumorigenesis in VSL#3-fed mice. We conclude that VSL#3 interventional therapy can alter microbial community composition and enhance tumorigenesis in the AOM/Ill10²/² model.
have been detected at increased abundance in human CRC tissue, as reported in IBD patients, and in mouse models of colitis and CRC.

VSL#3 is a commercially available probiotic cocktail (Sigma-Tau Pharmaceuticals, Inc.) of eight strains of lactic acid-producing bacteria: Lactobacillus plantarum, Lactobacillus delbrueckii subsp. Bulgaricus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, and Streptococcus salivarius subsp. Thermophilus. Orally administered VSL#3 has shown success in ameliorating symptoms and reducing inflammation in human poushitis and ulcerative colitis. Preventive VSL#3 administration can also attenuate colitis in II10−/− mice and ileitis in SAMP1/YitFc mice. Nonetheless, several reports indicate no beneficial effects of VSL#3 on murine dextran sulfate sodium (DSS) colitis, established ileitis in TNF2−/− mice, or human poushitis. The mechanisms underlying the beneficial functions of VSL#3 are not well understood, but likely involve direct effects of probiotic activity on the mammalian host as well as indirect effects by altering the population dynamics of the gut microbiota as a whole. Indeed, pre-treatment with VSL#3 altered community composition, prevented DSS colitis, and diminished adenoma and adenocarcinoma formation in the AOM/DSS model. In the rat TNBS model of inflammation-associated CRC, early administration of VSL#3 altered microbial diversity and delayed the transition from inflammation to dysplasia. Thus it is clear that VSL#3 probiotic has the capability to prevent inflammation and carcinogenesis when used as a preventative strategy. However, the therapeutic potential of VSL#3 probiotic administered after the onset of inflammation remains unknown.

The goal of the present study was to assess the ability of probiotic cocktail VSL#3 to alter the colonic microbiota and decrease inflammation-associated cancer when administered as interventional therapy. We report that therapeutic administration of VSL#3 probiotic did not protect against the development of colitis-associated CRC or inflammation in AOM/II10−/− mice. In fact, we observed increased tumorigenesis in one of two cohorts of VSL#3-fed mice, relative to VSL#3-untreated mice. Illumina sequencing of this microbiota revealed that microbial community composition of the stool and mucosally-adherent compartments were significantly altered by VSL#3 administration. Depletion of a bacterial taxon assigned to genus Clostridium from the mucosally-adherent microbiota was identified as a mediator of VSL#3-enhanced tumorigenesis in this cohort. Together these findings demonstrate that therapeutic administration of VSL#3 does not protect against tumorigenesis in AOM/II10−/− mice and may promote the loss of potentially protective microorganisms from the mucosally-adherent microbiota.

**Results**

**VSL#3 does not protect against tumorigenesis in the AOM/II10−/− model of colitis-associated CRC.** To investigate the impact of probiotic intervention on development of colitis-associated CRC, we conventionalized germ-free (GF) II10−/− mice with specific pathogen free (SPF) microbiota for seven weeks to establish intestinal inflammation. Conventionalizing mice born and raised in GF conditions negates the confounding factor of familial transmission of the microbiota. Tumorigenesis was then initiated with weekly i.p. injections of AOM (10 mg/kg), at which point daily oral administration of VSL#3 (10⁹ CFU/animal/day) was begun (Fig. 1).

Based on previous reports showing that preventive administration of VSL#3 can reduce dysplasia and tumorigenesis in experimental models of inflammation-associated CRC, we hypothesized that interventional treatment would reduce tumorigenesis in the AOM/II10−/− model. However, macroscopic assessment of tumor penetrance revealed no significant effect of VSL#3 on tumorigenesis, assessed seventeen weeks after the initial AOM injection (Fig. 2a). Microscopic scoring of neoplasia revealed high-grade dysplasia in 18/19 mice, with no significant difference in dysplasia score between VSL#3-treated and VSL#3-untreated animals (Fig. 2b). There was a potential trend towards greater depth of tumor invasion in VSL#3-treated animals that did not reach significance (Fig. 2c, chi-squared test p = 0.095).

To gain a better insight into VSL#3 effects on colitis-associated CRC in respect to microbial composition, we repeated the experiment using a second cohort of II10−/− mice. Seventeen weeks after the initiation of tumorigenesis with AOM, miniature endoscopy of live anesthetized mice revealed large macroscopic lesions in VSL#3-treated animals that were rarely seen in VSL#3-untreated animals (Fig. 3a). Macroscopic examination of harvested colon tissue revealed that VSL#3-treatment induced visible tumors in 91% of mice, a significantly greater amount than the 38% observed in VSL#3-untreated mice that developed macroscopic lesions (Fig. 3b, c). Tumor multiplicity was also significantly enhanced by VSL#3, revealing that VSL#3-treatment induced visible tumors in 91% of mice, a significantly greater amount than the 38% observed in VSL#3-untreated mice that developed macroscopic lesions (Fig. 3b, c). Tumor multiplicity was also significantly enhanced by VSL#3,

**Figure 1** | Experimental timeline for AOM/II10−/− model with VSL#3 interventional administration. Germ-free II10−/− mice were transferred to SPF conditions where they were colonized with SPF commensal bacteria for seven weeks. Tumorigenesis was then initiated with weekly injections of AOM (10 mg/kg), and VSL#3 was orally administered (10⁹ CFU/mouse/day) to mice daily throughout the remainder of the experiment. After twenty-four weeks, mice were sacrificed and tissues were harvested for assessment of microbiota, inflammation, and tumorigenesis.

**Figure 2** | VSL#3 does not affect tumorigenesis in AOM II10−/− mice. (a) Tumor penetrance, non-significant by one sample t test comparing SPF + VSL#3 group to SPF control at 100%, p = 0.341. (b) dysplasia score, non-significant by two-tailed Mann Whitney U test, p = 0.315. Bar graphs (a–b) depict mean ± SEM. (c) Tumor invasion, comparisons by chi-squared test, p = 0.095. (a–c) SPF n = 8, SPF + VSL#3 n = 11.
with an average of 1.64 macroscopic tumors per mouse vs. 0.33 tumors per mouse in VSL#3-untreated animals (Fig. 3d). Tumor size, however, remained unaffected by VSL#3 treatment (Fig. 3e). Histologic analysis of colonic sections revealed a significantly enhanced dysplasia score in VSL#3-treated animals (Fig. 3f). As observed in the first cohort, the cancer in VSL#3-fed animals was highly penetrant, with nearly all animals exhibiting advanced neoplasia (Fig. 3g). The majority of the VSL#3-fed mice harbored invasive adenocarcinomas (79% of mice), in contrast to only 13% of VSL#3-untreated mice (Fig. 3h, i). These results indicate that interventional treatment with VSL#3 does not protect against, and has the ability to enhance, tumorigenesis and tumor invasion in the AOM/Ill10<sup>-/-</sup> model of colitis-associated CRC.

**VSL#3 treatment does not impact colonic inflammation in the AOM/Ill10<sup>-/-</sup> model.** Chronic inflammation has been recognized as an important risk factor for CRC. We next assessed histologic inflammation in the distal and proximal colon of our second cohort of AOM/Ill10<sup>-/-</sup> mice treated with or without VSL#3. We observed no significant difference in inflammation scores (Fig. 4a,
IBD and CRC patients have a dysbiotic microbiota\(^6,9,12,13\). In stool and mucosally-adherent microbiota, VSL#3 alters the abundance of specific bacterial taxa of the luminal/mucosally-adherent microbiota. At a trend toward lower diversity in the luminal microbiota of SPF+VSL#3 mice relative to mean expression of four mice in the SPF group; line at median. Data analysis was performed with SA Bioscience RT\(^2\) Profiler PCR Array Data Analysis version 3.4 using the \(\Delta \Delta C_t\) method and two-tailed Student t test.

VSL#3 alters community composition of both the luminal/stool and mucosally-adherent microbiota. Previous studies indicate that IBD and CRC patients have a dysbiotic microbiota\(^8,9,12,13\). In addition, we have previously demonstrated a bloom of Enterobacteriaceae in AOM/\(\Delta I_{110}\)/mice\(^8\). To determine the extent to which VSL#3 alters the microbiota, we utilized Illumina HiSeq2000 high-throughput sequencing. We extracted DNA from stool samples to assess the luminal microbiota and from colon tissue biopsies to assess the mucosally-adherent microbiota and sequenced the hypervariable V6 region of the 16S rRNA gene\(^8\). We sequenced the luminal microbiota of all animals, and one representative animal per cage. To gain greater insight into the inflammatory environment of the colon, we measured inflammatory cytokine mRNA in colon tissue biopsies using an Inflammation PCR Array. There were no significant differences in the expression of common IBD- and CRC-associated cytokines including \(\text{Ifng, Il1b, Il23a}\) and \(\text{Il6}\) (Fig 4c). Together these results suggest that VSL#3 enhances tumorigenesis without augmenting host inflammatory status.

VSL#3 alters the abundance of specific bacterial taxa of the luminal/stool and mucosally-adherent microbiota. To gain greater insight into the inflammatory environment of the colon, we measured inflammatory cytokine mRNA in colon tissue biopsies using an Inflammation PCR Array. There were no significant differences in the expression of common IBD- and CRC-associated cytokines including \(\text{Ifng, Il1b, Il23a}\) and \(\text{Il6}\) (Fig 4c). Together these results suggest that VSL#3 enhances tumorigenesis without augmenting host inflammatory status.

Figure 4 | VSL#3 does not significantly impact inflammation in AOM/\(\Delta I_{110}\)/mice. (a) Distal, and (b) proximal colon histologic inflammation scores, mean \pm SEM, 13–14 mice/group, pairwise comparisons by two-tailed Student t test. (c) Colonic cytokine mRNA expression of four individual SPF+VSL#3 mice relative to mean expression of four mice in the SPF group; line at median. Data analysis was performed with SA Bioscience RT\(^2\) Profiler PCR Array Data Analysis version 3.4 using the \(\Delta \Delta C_t\) method and two-tailed Student t test.

VSL#3 alters community composition of both the luminal/stool and mucosally-adherent microbiota. Previous studies indicate that IBD and CRC patients have a dysbiotic microbiota\(^8,9,12,13\). In addition, we have previously demonstrated a bloom of Enterobacteriaceae in AOM/\(\Delta I_{110}\)/mice\(^8\). To determine the extent to which VSL#3 alters the microbiota, we utilized Illumina HiSeq2000 high-throughput sequencing. We extracted DNA from stool samples to assess the luminal microbiota and from colon tissue biopsies to assess the mucosally-adherent microbiota and sequenced the hypervariable V6 region of the 16S rRNA gene\(^8\). We sequenced the luminal microbiota of all animals, and one representative animal per cage for the mucosally-adherent microbiota. We found that VSL#3 treatment altered both the luminal (ANOSIM \(R=0.381, P=0.032\)) and mucosally-adherent (ANOSIM \(R=0.406, P=0.024\)) microbiota (Figure 5a). As expected, the composition of the luminal compartment differed from that of the mucosally-adherent microbiota (ANOSIM \(R=0.466, P<0.001\)). Diversity of the luminal and mucosally-adherent microbiota (Figure 5b and c) were not significantly altered by VSL#3 treatment, although there was a trend toward lower diversity in the luminal microbiota of VSL#3-fed animals.

VSL#3 alters the abundance of specific bacterial taxa of the luminal/stool and mucosally-adherent microbiota. To gain greater insight into the inflammatory environment of the colon, we measured inflammatory cytokine mRNA in colon tissue biopsies using an Inflammation PCR Array. There were no significant differences in the expression of common IBD- and CRC-associated cytokines including \(\text{Ifng, Il1b, Il23a}\) and \(\text{Il6}\) (Fig 4c). Together these results suggest that VSL#3 enhances tumorigenesis without augmenting host inflammatory status.

Figure 5 | VSL#3 (filled symbols) alters community composition of the luminal/stool (blue circles) and mucosally-adherent (red squares) microbiota. (a) Operational taxonomic unit (OTU) abundances were standardized by total, log-transformed, and assembled into a Bray Curtis similarity matrix to generate a multidimensional scaling (MDS) plot, where each symbol represents the microbiota of an individual mouse analyzed by Illumina sequencing of V6 16S. Analysis of similarity (ANOSIM) was used to test for dissimilarity between groups, where \(R=1\) is maximum dissimilarity. As expected, the luminal/stool microbiota differs from that of the mucosally-adherent microbiota, regardless of VSL#3 treatment (ANOSIM stool vs. adherent, \(R=0.466, P<0.001\)). (b–c) VSL#3 does not affect Shannon diversity, Margalef richness or Pielou evenness of the (b) mucosally-adherent or (c) luminal microbiota. Bar graphs depict the mean diversity, richness or evenness of (b) mean \pm SEM; SPF = 5 mice, SPF+VSL#3 = 4 mice, or (c) cage means \pm SEM (to correct for cage effects); SPF = 10 mice in 4 cages, SPF+VSL#3 = 14 mice in 5 cages. (b–c) Pairwise comparisons were made using Student t test.
into the microbial changes elicited by VSL#3 administration, we used BLASTn™ to map the operational taxonomic unit (OTU) consensus sequences to the Silva database (http://www.arb-silva.de/) and classified the reference sequences using the RPD classifier. In both the luminal/stool and mucosally-adherent compartments, VSL#3 administration altered the phylum-level distribution of the microbiota, with differences achieving significance at a false discovery rate (FDR) < 10% (Figure 6). VSL#3-treated animals exhibited a significant contraction of Verrucomicrobia and expansion of Proteobacteria in the mucosally-adherent microbiota. Within the luminal/stool microbiota, the abundance of Bacteroidetes was significantly decreased by VSL#3 treatment while Proteobacteria remained unaffected. To determine which specific microbial groups may be altered by VSL#3 treatment, we assessed the family-level distribution of the luminal/stool and mucosally-adherent microbiota. We were able to classify ~99% of reference sequences mapped to our OTUs to family level. At both the luminal/stool and mucosally-adherent compartments, VSL#3 treatment induced a contraction of Porphyromonadaceae and in the adherent compartment, also a contraction of Verrucomicrobiaceae (Figure 7). These changes were significant at FDR < 0.05 but not < 10% FDR, likely due to the large number of microbial families surveyed. Depletion, rather than expansion, of specific microbial groups in response to VSL#3 treatment suggests that a loss of protective microbes contributed to the significantly enhanced penetrance and severity of tumorigenesis in this model.

Depletion of a Clostridium bacterial group is associated with VSL#3 administration and tumorigenesis. To determine if microbial alterations in the mucosally-adherent microbiota mediate the effects of VSL#3 on tumorigenesis, we performed mediation by linear models analysis (Figure 8a and Methods section). In this analysis, we first tested the effect of VSL#3 on dysplasia (model 1). In agreement with earlier results presented in Figure 2, we found that VSL#3 was significantly associated with dysplasia score (P < 0.0008). We next applied model 2 to test the association of the relative abundance of all OTUs of the mucosally-adherent microbiota with dysplasia. We found that only a single taxon of the mucosal niche, OTU#199, had a significant association with dysplasia score (Benjamini and Hochberg FDR corrected p = 0.0518). The consensus sequence of OTU#199 has an exact match to 38 distinct Clostridium taxa in the Silva database, and all of these full-length sequences were classified as Clostridiaceae I by RDP with a confidence score of 99% and Clostridium sensu stricto with a confidence score of 52%.

We next applied model 3, which indicated that VSL#3 treatment was associated with a significant (~16 fold) decrease in the relative abundance of OTU#199 (FDR corrected P = 0.0525; Figure 8b). Although the relative abundance of one other OTU of the mucosally-adherent microbiota was reduced in VSL#3 treated mice (FDR corrected p = 0.00073), model 2 analysis revealed that this OTU (best classified as Blautia sp., accession GQ493997.1.1354) was not associated with dysplasia (FDR corrected p > 0.10). From these combined results, we concluded that depletion of a mucosally-adherent Clostridium group was a potential mediator of the effects of VSL#3 on dysplasia/tumorigenesis.

To further evaluate this possibility, we applied model 4. We tested the effect of VSL#3 on dysplasia score without the influence of OTU#199, and found a high P-value (0.9399), which indicates that VSL#3 treatment is not directly associated with dysplasia. In contrast, when we tested the effect of OTU#199 on dysplasia score without the influence of VSL#3, we found a low P-value (FDR corrected P = 0.0692), supporting that the abundance of OTU#199 is associated with dysplasia. Taken together, the combined results of this mediation analysis by linear models indicated that depletion of OTU#199, a bacterial group of the genus Clostridium, is a potential mediator of the effects of VSL#3 on dysplasia/tumorigenesis in our experiment. These results demonstrate that VSL#3 may enhance dysplasia/tumorigenesis through depletion of Clostridium bacteria (OTU#199) at the mucosal niche.

Discussion

Intake of probiotics as a means to maintain health and alleviate disease symptoms, especially gastrointestinal disorders, has gained tremendous popularity worldwide. Although some of the beneficial impacts of probiotics have been scientifically documented, mechanisms of action and impact on established disease remained unclear. Introduction of billions of bacteria in a confined ecosystem such as the intestine is likely to impact the microbial community. Earlier work employing molecular fingerprinting analyses, including terminal restriction fragment length polymorphism (TRFLP) and denaturing gradient gel electrophoresis (DGGE), have revealed that administration of VSL#3 probiotic can alter microbial community composition of mice and rats. To better understand the impact of interventional VSL#3 administration on the microbial community during development of colitis-associated CRC, we utilized high throughput Illumina 16S sequencing of the intestinal...
Interventional administration of VSL#3 altered the composition of the luminal and mucosally-adherent microbiota with phylum level changes in the luminal microbiota (decrease in Bacteroidetes) and mucosally-adherent microbiota (decrease in Verrucomicrobia and increase in Proteobacteria). Depletion of specific bacterial groups at the family level, with Verrucomicrobiaceae in the adherent compartment and Porphyromonadaceae in the luminal and adherent compartments, was observed in VSL#3-exposed mice. Although we detected a non-significant increase in the abundance of VSL#3 bacterial groups Firmicutes and Lactobacillaceae, the major differences were detected in non-VSL#3 bacterial groups, indicating that administration of VSL#3 can exert pressure to induce broad changes in the microbial population of the intestine. These findings clearly demonstrate that VSL#3 administration markedly changed the composition of both the luminal and mucosally-associated microbiota.

In contrast to other studies where prophylactic VSL#3 administration ameliorated colitis and colitis-associated CRC, our results have demonstrated that administration of VSL#3 beginning after the onset of inflammation and dysbiosis can enhance tumorigenesis. This was not associated with changes in inflammation or inflammatory cytokine profiles. Instead, enhanced tumorigenesis was associated with shifts in the composition of the intestinal microbiota in both the luminal/stool and mucosal niches. The initial composition of the microbial community likely influences probiotic effects on the host, as we also observed that prophylactic administration of VSL#3 beginning 3 days after transfer of Il10−/− mice from germ-free to SPF housing did not ameliorate inflammation nor early dysplasia (data not shown). In fact, we observed unexpected mortality in this treatment group, and terminated the experiment early at fourteen weeks post-transfer to SPF, six weeks after beginning AOM treatment (SPF vs. prophylactic VSL#3, log rank test p = 0.040).

Altogether, these results suggest that probiotics may be ineffective and even detrimental to host health in the context of an immature or dysbiotic microbiota.

An unexpected consequence of interventional administration of VSL#3 probiotic was the lack of a protective effect on tumorigenesis and the propensity to enhance tumor invasion in AOM/Il10−/− mice. We have previously demonstrated that inflammation in Il10−/− mice alters the composition of the intestinal microbiota with expansion of Proteobacteria, and this impacts the development of CRC. In the current study, VSL#3 was therapeutically administered after the onset of inflammation and in the context of a dysbiotic microbiota. In contrast to other studies where prophylactic VSL#3 administration ameliorated colitis and colitis-associated CRC, our results have demonstrated that administration of VSL#3 beginning after the onset of inflammation and dysbiosis can enhance tumorigenesis. This was not associated with changes in inflammation or inflammatory cytokine profiles. Instead, enhanced tumorigenesis was associated with shifts in the composition of the intestinal microbiota in both the luminal/stool and mucosal niches. The initial composition of the microbial community likely influences probiotic effects on the host, as we also observed that prophylactic administration of VSL#3 beginning 3 days after transfer of Il10−/− mice from germ-free to SPF housing did not ameliorate inflammation nor early dysplasia (data not shown). In fact, we observed unexpected mortality in this treatment group, and terminated the experiment early at fourteen weeks post-transfer to SPF, six weeks after beginning AOM treatment (SPF vs. prophylactic VSL#3, log rank test p = 0.040). Altogether, these results suggest that probiotics may be ineffective and even detrimental to host health in the context of an immature or dysbiotic microbiota.

It also appeared that administration of VSL#3 predominantly induced depletion of bacterial groups, suggesting that tumorigenesis was enhanced through the loss of protective commensal bacteria. To determine if specific bacterial groups (classified into OTUs of 97% similarity) of the mucosally-adherent microbiota mediated the
Several of these species matched the consensus sequence of the sub-genus of *Clostridium* in our model. This approach, termed mediation by linear models, was applied for multiple testing correction (model 2). A detailed description of the models is provided in Materials and Methods. (b) OTU #199, assigned to genus *Clostridium*, median log-normalized abundance + SEM. FDR-corrected P-value is shown, uncorrected P-value = 0.0002. SPF n = 5, SPF + VSL#3 n = 4.

Figure 8 | Depletion of mucosally-adherent *Clostridium* bacteria mediates the effects of VSL#3 on dysplasia/tumorigenesis. (a) Mediation analysis by linear models was performed between VSL#3 status, dysplasia score, and each OTU in the stool or mucosally-adherent microbiota. Results for OTU #199 are shown. P < 0.10 was used as cutoff. The Benjamini and Hochberg FDR adjustment was applied for multiple testing correction (model 2). A detailed description of the models is provided in Materials and Methods. (b) OTU #199, assigned to genus *Clostridium*, median log-normalized abundance + SEM. FDR-corrected P-value is shown, uncorrected P-value = 0.0002. SPF n = 5, SPF + VSL#3 n = 4.

Effects of VSL#3 administration on tumorigenesis, we utilized a statistical approach termed mediation by linear models. This approach first revealed that at a FDR corrected cutoff of P < 0.1, only one OTU of the mucosally-adherent microbiota, belonging to genus *Clostridium*, was a potential mediator of VSL#3 effects on tumorigenesis in our model. *Clostridium* sensu stricto, the sub-genus to which *RDP* classified this OTU with 52% confidence, is the largest sub-genus of *Clostridium* and comprises approximately 73 species. Several of these species matched the consensus sequence of OTU#199 at 100% identity in the Silva database. *Clostridium* species have recently been shown to provide protection by inducing IL-10-producing intestinal T-regulatory cells, however, this trait is mainly attributed to Clostridium cluster IV and XIVA. A major mechanism by which T-regulatory cells maintain homeostasis in the intestine is the production of IL-10. This protective mechanism is not intact in *II10*−/− mice, thus it is unlikely that depletion of IL-10-producing T-regulatory cells is responsible for enhanced tumorigenesis in VSL#3-treated AOM/II10−/− mice. An IL-10-independent mechanism of protection in the intestine is consistent with early work in which colitis was prevented in *II10*−/− mice by prophylactic administration of VSL#3, which was associated with an enhancement of epithelial barrier function. At this time, the impact of VSL#3 and depletion of *Clostridium* species on epithelial barrier function in our colitis-associated CRC model is unknown. In addition, future studies will be necessary to determine if VSL#3 induces the depletion of *Clostridium* species in other CRC models and in the absence of disease in healthy WT mice. Many *Clostridium* can ferment dietary fiber and host mucins to produce short chain fatty acids such as butyrate. Butyrate serves as a primary energy source for healthy colonicocytes and regulates gene expression, inflammation, differentiation, and apoptosis in the intestine. Butyrate and butyrate-producing bacteria have anti-inflammatory and anti-carcinogenic activities, and butyrate-producing bacteria are depleted in human IBD and CRC. Thus depletion of *Clostridium* OTU#199 from the mucosally-adherent microbiota may reduce the production of butyrate and its anti-carcinogenic effects, resulting in enhanced tumorigenesis in AOM/II10−/− mice. Butyrate and other short chain fatty acids are notoriously difficult to measure in vivo, however, if this hypothesis is correct, restoring the availability of butyrate in the intestine via prebiotic and/or novel probiotic supplementation with *Clostridium* could reveal a novel means by which to protect against IBD and CRC. Future studies will be necessary to determine if supplementation with any of the numerous bacteria represented by OTU#199 can promote protection or prevent VSL#3-induced enhancement of tumorigenesis in the AOM/II10−/− model.

Together, our findings highlight several important concepts. First, probiotic bacteria may fail to protect against tumorigenesis in an environment with established dysbiosis. Earlier studies have revealed that VSL#3 probiotic can provide protection against colitis and colitis-associated CRC when VSL#3 is administered prior to the onset of inflammation and also in a subset of human IBD patients. It is possible that IL-10-independent effects of VSL#3 administration are not sufficient to overcome the pro-inflammatory and pro-carcinogenic effects of established dysbiosis in the AOM/II10−/− model. Second, probiotic bacteria can alter the composition of the luminal and mucosally-adherent microbiota and induce the depletion of endogenous beneficial microbes at the mucosal niche. In the current study, we observed a detrimental effect that was potentially mediated by the loss of *Clostridium* bacteria. Given the complexity in the microbiota, it is not surprising to find evidence that certain bacteria may protect against inflammation while others protect against the progression of neoplasia. Undoubtedly, greater accessibility of new ‘omics technologies will allow for a better understanding of the tremendously metabolic capacity of the microbiota and how microbial activities can be modulated to promote health and protect against disease.

**Methods**

AOM/II10−/− model and probiotic administration. *II10*-deficient 129/SvEv mice were born and raised in germ-free (GF) isolators and then transferred directly to our specific pathogen free (SPF) facility (age 7–12 weeks, housed 2–4 mice per cage) for the immediate initiation of our colitis/colorectal cancer experiment (Fig. 1). In this model, mice naturally acquire the microbiota from their cage/room environment. This method of conventionalization negates any confounding familiar or maternal transmission of the microbiota. We have recently characterized the microbiota of this model. After 7 weeks of colonization with SPF bacteria, mice received 6 weekly i.p. injections of azoxymethane (AOM, 10 mg/kg). On the day of the first AOM injection, one group of mice was orally administered VSL#3 probiotic (Sigma-Tau Pharmaceuticals, Inc.), 10⁹ CFU per animal each day during the week, with two days off on weekends, until the end of the experiment. The second group was not administered VSL#3 probiotic. After 17 weeks (24 weeks post-transfer from GF housing), miniature endoscopy was performed to visualize tumor development in live mice. Mice were sacrificed, stool and tissue were collected, and colon was examined macroscopically for tumors then swiss-rolled and fixed in formalin for paraffin embedding and histology. Histology was scored for inflammation and dysplasia/tumors by two blinded experienced investigators and reviewed by an independent panel. This process was repeated for the VSL#3 treated group. Significance was calculated using the Chi-square test with a p-value of 0.05.
expert animal histopathologist. Dysplasia scoring was as follows: 0 = no dysplasia, 1 = mild dysplasia characterized by aberrant crypt foci (ACF), +0.5 for multiple 2 = gastrointestinal neoplasia (GIN), +0.5 for multiples 3 = adenoma, non-invasive severe or high grade dysplasia restricted to the mucosa; 3.5 = adenocarcinoma, invasive through the muscularis mucosa; 4 = adenocarcinoma, fully invasive through the submucosa and into or through the muscularis propria. Two independent expert animal histopathologists were consulted and data from both experiments are reported and discussed. All animal protocols were approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill.

**DNA extraction.** Stool samples and mucosal biopsies were collected to assess luminal and mucosally-adenherent microbiota respectively. Colon biopsies (2 x 10 mm) were collected after flushing the colon with PBS. Samples were immediately stored at −80°C. DNA was extracted from between 50–200 mg of stool or 100 mg colon tissue as described.

**Illumina V6 16S library construction.** The V6 hypervariable region of the 16S rRNA gene was amplified using a two-step PCR strategy. The first step uses primers to the V6 region of the 16S gene that contain a 4-6 nucleotide barcode for multiplexing. The subsequent PCR adds Illumina paired-end sequencing adapters and a flow-cell adapter on the 5’ and 3’ ends of the amplicons. Amplicons were visualized on 1.5% agarose gel and purified using the QIAquick PCR purification kit (Qiagen). 50 ng of DNA from each sample was pooled to a final concentration of 29 ng/ml and subjected to paired-end Illumina HiSeq2000 sequencing at the University of North Carolina High Throughput Sequencing Facility.

**Illumina sequencing.** A single lane of Illumina HiSeq2000 generated 57,184,070 paired-end sequences (144 multiplexed samples, 33 for this study) with a length read of − 75 bases, excluding primer sequences. Raw sequences were processed as described except that we required at least 70 continuous matching nucleotides across the length of the untagged alignment to generate each consensus sequence. A total of 39,337,745 paired-end sequences met our merging and extending criteria for the whole lane and 8,332,581 sequences belonged to the current study. Those 8,332,581 consensus sequences were fed in three batches into the program AbundantOTU v.2.0 (http://omics.informatics.indiana.edu/AbundantOTU/) with default parameters. The first batch represented all 33 samples, the second represented only luminal/stool (LS) samples (24 samples, 5,568,718 consensus sequences) and the third represented mucosally-adenherent (MA) samples (9 samples, 2,963,863 consensus sequences). AbundantOTU clustered these sequences into 1,064 (all), 439 (LS) and 857 (MA) Operational Taxonomic Units (OTUs). AbundantOTU incorporated 8,512,390 (99.76%) of all consensus sequences, 5,548,738 (99.64%) of the LS samples and 2,957,301 (99.78%) of the MA samples. The sequences that were not incorporated into an OTU were further analyzed. A UCHIME v. 4.2.40 (http://www.drive5.com/uchime/) search using the Gold reference database was used to detect the presence of chimeras in our OTUs. UCHIME reported 6 (all), 3 (LS) and 2 (MA) chimeras representing a negligible fraction of the total consensus sequences that were incorporated into OTUs. All reported chimeras were excluded from further analyses.

To facilitate taxonomic classification and to compensate for the short read length of the generated OTUs, we used BLASTn (v. 2.2.26 +) with an expectation value threshold of e-5 to map the OTU sequences to the Silva database (release 108, http://www.arb-silva.de/). Next, we utilized the standalone version of the RDP classifier (v. 2.5.0 +) to assign each Silva sequence to the best OTU match to the OTU sequence requiring an RDP confidence score of ≥ 80%.

Given the short read length of our Illumina V6 amplicon (~75 basepairs), we were unable to rigorously classify all OTUs, including #199, to species. In the Silva database, there were 38 full-length 16S sequences with an exact match to the consensus sequence of OTU #199. All were classified to genus Clostridium. RDP classified the consensus sequence for OTU #199 as Clostridiaceae I with 99% confidence and the sub-genus Clostridium sensu stricto with 52% confidence. Longer amplicons will be required to narrow this taxonomic assignment in future work.

**Statistics.** Statistical tests are described in figure legends and were computed using PRIMER v. 6, Microsoft Excel, Graphpad Prism, R v. 2.15.1 (http://www.R-project.org), and/or SAS v.9.2 (SAS Institute Inc., Cary, NC). All tests are two-tailed, alpha = 0.05. For microbiota analyses, OTU abundances were standardized to relative abundance, log-transformed, and analyzed with a Bray-Curtis similarity matrix using PRIMER v. 6 (PRIMERe, Inc.). Analysis of Similarity (ANOSIM) was used to test for dissimilarity in community composition, and ordination plots were generated by multidimensional scaling (MDS). ANOSIM was nested on the cage for the luminal microbiota; cage was not a factor for the mucosally-adenherent microbiota as we assessed just one representative animal per cage. Before performing ANOSIM, we removed OTUs represented in ≤ 25% of samples. Diversity was assessed by calculating Shannon diversity index, Margalef richness index and Pielou evenness index. For calculation of P-values for diversity in the luminal microbiota, mean from all mice within a cage was utilized as an observational replicate. To compare the abundance of individual taxa between groups, we performed pairwise comparisons within the mucosally-adenherent microbiota by t-test and in the luminal/stool microbiota by fitting a mixed effect linear model of the form: $T = i + c_1 V + c_2 G(V)$ + e where T represents the Log Normalized Count; V represents treatment (VSL#3 or non-VSL#3); G represents the cage; i is the intercept; c1 and c2 are coefficients for independent variables; e is the residual. This model takes into account the fact that multiple cages are involved and could contribute to the variation detected between samples. VSL#3 was treated as a fixed effect while cage nested within VSL#3, the term G(V), in the model, was considered a random effect. All P-values were corrected for multiple testing using the Benjamini and Hochberg procedure ($\alpha = \min(n/n'p /R)$ where n = # taxa, p = test P-value, R = rank by raw P-value) at a false discovery rate (FDR) 0.10 was considered significant. As all four models belong to one analysis, a single P < 0.10 cutoff was applied. Each taxon was tested separately for its mediation effect.

**Inflammation PCR arrays.** Inflammatory gene expression was evaluated using SABiosciences array as described by us. Briefly, RNA was extracted from distal colon biopsies (4 per group) using phenolchloroform, DNase treatment (Qiagen) and RNeasy kit (Qiagen/SABiosciences). 1 μg of RNA was transcribed to cDNA using RT2 First Strand kit (Qiagen/SABiosciences). Expression of inflammatory mediators was assessed using inflammatory array PAMM-077 (Qiagen/SABiosciences). Data analysis was performed with SABioscience RT2 Profiler PCR Array Data Analysis version 3.4 (Qiagen/SABiosciences: http://pcrdataanalysis.sabiosciences.com/prcr/ arrayanalysis.php) using the ΔΔCt method after normalizing to five housekeeping genes. Data are presented as fold changes for four individual VSL#3-treated mice, relative to the mean of four SPF mice.

1. Klaenhammer, T. R., Kleerebezem, M., Kopp, M. V. & Rescigno, M. The impact of probiotics and prebiotics on the immune system. Nat. Rev. Immunol. 12, 728–734 (2012).
2. Gareau, M. G., Sherman, P. M. & Walker, W. A. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 7, 503–514 (2010).
3. Manichanh, C., Borruel, N., Casellas, F. & Guarner, F. The gut microbiota in IBD. Gut Microbes 2, 13780–13785 (2007).
4. Isaacs, K. & Herfarth, H. Role of probiotic therapy in IBD. Inflammatory bowel disease. 139, 858–867 (2008).
5. Willing, B. P. et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139, 1844–1854 e1 (2010).
6. Sibbani, L. et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS ONE 6, e16393 (2011).
7. Schwartzberg, N. et al. Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. ISME J 6, 1588–1688 (2012).
8. Shen, X. J. et al. Molecular characterization of mucosal adherent bacteria and associations with colorectal cancer. Gut Microbes 1, 138–147 (2010).
9. Jobin, C. Colorectal cancer: looking for answers in the microbiota. Gastroenterology 115, 281–286 (1998).
